Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Sermer

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Hematological Oncology|June 13, 2019
CAR T-cell therapy: Full speed aheadDavid Sermer, Renier Brentjens
American Journal of Medical Genetics. Part A|November 15, 2007
Acrofacial dysostosis syndrome type Rodriguez: prenatal diagnosis and autopsy findingsDavid Sermer, Nada Quercia, Karen Chong, et al.
The Oncologist|December 25, 2012
Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug AdministrationRobert E Martell, David Sermer, Kenneth Getz, et al.
Nature Reviews. Clinical Oncology|March 7, 2019
Emerging epigenetic-modulating therapies in lymphomaDavid Sermer, Laura Pasqualucci, Hans-Guido Wendel, et al.
Expert Review of Anticancer Therapy|April 11, 2022
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemiaShayna Sarosiek, David Sermer, Andrew R Branagan, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 27, 2022
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström MacroglobulinemiaDavid Sermer, Shayna Sarosiek, Andrew R Branagan, et al.
Blood Reviews|August 21, 2022
Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportationDavid Sermer, Pavania Elavalakanar, Jeremy S Abramson, et al.
Leukemia & Lymphoma|February 9, 2023
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphomaHoa Van Le, Kim Van Naarden Braun, Grzegorz S Nowakowski, et al.
Blood|November 16, 2023
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemiaJorge J Castillo, Andrew R Branagan, David Sermer, et al.
Blood Cancer Journal|June 17, 2021
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapseSabela Bobillo, Erel Joffe, David Sermer, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Hematological Oncology|June 13, 2019
CAR T-cell therapy: Full speed aheadDavid Sermer, Renier Brentjens
American Journal of Medical Genetics. Part A|November 15, 2007
Acrofacial dysostosis syndrome type Rodriguez: prenatal diagnosis and autopsy findingsDavid Sermer, Nada Quercia, Karen Chong, et al.
The Oncologist|December 25, 2012
Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug AdministrationRobert E Martell, David Sermer, Kenneth Getz, et al.
Nature Reviews. Clinical Oncology|March 7, 2019
Emerging epigenetic-modulating therapies in lymphomaDavid Sermer, Laura Pasqualucci, Hans-Guido Wendel, et al.
Expert Review of Anticancer Therapy|April 11, 2022
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemiaShayna Sarosiek, David Sermer, Andrew R Branagan, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 27, 2022
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström MacroglobulinemiaDavid Sermer, Shayna Sarosiek, Andrew R Branagan, et al.
Blood Reviews|August 21, 2022
Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportationDavid Sermer, Pavania Elavalakanar, Jeremy S Abramson, et al.
Leukemia & Lymphoma|February 9, 2023
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphomaHoa Van Le, Kim Van Naarden Braun, Grzegorz S Nowakowski, et al.
Blood|November 16, 2023
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemiaJorge J Castillo, Andrew R Branagan, David Sermer, et al.
Blood Cancer Journal|June 17, 2021
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapseSabela Bobillo, Erel Joffe, David Sermer, et al.
Pageof 2